190 related articles for article (PubMed ID: 29455269)
21. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review.
Zou K; Yang S; Zheng L; Yang C; Xiong B
BMC Cancer; 2016 Sep; 16(1):737. PubMed ID: 27633381
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of apatinib combined with S-1 for advanced gastric cancer: A systematic review and meta-analysis.
Chen X; Wan L; He Y; Zhang Q; Zheng X
Medicine (Baltimore); 2024 May; 103(21):e38272. PubMed ID: 38787998
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.
Chen H; Lu W; Zhang Y; Zhu X; Zhou J; Chen Y
Cancer Med; 2019 Jan; 8(1):383-399. PubMed ID: 30525293
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials.
Pan S; Li K; Huang B; Huang J; Xu H; Zhu Z
Ann Transl Med; 2021 Feb; 9(4):290. PubMed ID: 33708917
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
27. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer.
Xiong BH; Cheng Y; Ma L; Zhang CQ
Cancer Invest; 2014 Jul; 32(6):272-84. PubMed ID: 24800782
[TBL] [Abstract][Full Text] [Related]
28. A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer.
Zhu X; Ko YJ; Berry S; Shah K; Lee E; Chan K
Gastric Cancer; 2017 Jul; 20(4):646-654. PubMed ID: 27722826
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies.
Iacovelli R; Pietrantonio F; Farcomeni A; Maggi C; Palazzo A; Ricchini F; de Braud F; Di Bartolomeo M
PLoS One; 2014; 9(9):e108940. PubMed ID: 25268988
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.
Sun J; Ren Z; Sun X; Hou H; Li K; Ge Q
Oncotarget; 2017 Jun; 8(24):39673-39682. PubMed ID: 28562333
[TBL] [Abstract][Full Text] [Related]
32. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
Hong C; Mei T; Wang J
Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
[TBL] [Abstract][Full Text] [Related]
33. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.
Ge L; Tang Y; Zhang QN; Tian JH; Wang XH; Pieper D; Pan B; Li L; Ling J; Bing ZT; Yang KH
Oncotarget; 2017 Aug; 8(35):59539-59551. PubMed ID: 28938657
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials.
Mai R; Zhou S; Zhong W; Rong S; Cong Z; Li Y; Xie Q; Chen H; Li X; Liu S; Cheng Y; Huang Y; Zhou Y; Zhang G
Oncotarget; 2015 Sep; 6(29):28502-12. PubMed ID: 26143635
[TBL] [Abstract][Full Text] [Related]
35. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis.
; Oba K; Paoletti X; Bang YJ; Bleiberg H; Burzykowski T; Fuse N; Michiels S; Morita S; Ohashi Y; Pignon JP; Rougier P; Sakamoto J; Sargent D; Sasako M; Shitara K; Tsuburaya A; Van Cutsem E; Buyse M
Eur J Cancer; 2013 May; 49(7):1565-77. PubMed ID: 23352439
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
Lin WZ; Xu QN; Wang HB; Li XY
Breast Cancer; 2017 May; 24(3):345-352. PubMed ID: 28324247
[TBL] [Abstract][Full Text] [Related]
37. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
38. Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.
Qian X; Qin J; Pan S; Li X; Pan Y; Ma S
PLoS One; 2015; 10(9):e0139026. PubMed ID: 26402447
[TBL] [Abstract][Full Text] [Related]
39. [Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
Yang MD; Gao J; Liu XL; Yang WH; Lu HX
Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):594-597. PubMed ID: 32842450
[No Abstract] [Full Text] [Related]
40. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
